BTCS vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 13, 2026

BTCS

40.5
AI Score
VS
HIVE Wins

HIVE

57.5
AI Score

Investment Advisor Scores

BTCS

41score
Recommendation
HOLD

HIVE

58score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric BTCS HIVE Winner
Forward P/E 49.505 62.8931 BTCS
PEG Ratio 0 0 Tie
Revenue Growth 27.1% 130.5% HIVE
Earnings Growth -69.6% -99.9% BTCS
Tradestie Score 40.5/100 57.5/100 HIVE
Profit Margin 0.0% -49.9% BTCS
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

BTCS 1M: +33.7% · 3M: -21.1% HIVE 1M: -4.7% · 3M: -21.3%

Current Technical Phase

BTCS

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 69

RSI (14): 69.3 · Price: $1.35

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.9 · Price: $3.03

Fundamentals Snapshot

Metric BTCS HIVE
Market Cap
Forward P/E 49.5 -5.9
Trailing P/E
Revenue (TTM)
Revenue Growth -0.1% 0.7%
Gross Margin 0.3% 0.4%
Operating Margin -0.7% -0.6%
EPS -2.47 -1.54
Dividend Yield 0.00%

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.